[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Omphis Foundation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100545211","selective-sentinella-lymph-node-biopsy-with-indocyanine-green-in-patients-with-breast-cancer-100545211",false,"NCT06378944","Selective Sentinella Lymph Node Biopsy with Indocyanine Green in Patients with Breast Cancer","INDOCYANINE GREEN for SELECTIVE SENTINELLA AXILLARY LYMPH NODE BIOPSY in PATIENTS with BREAST CANCER","INSEAN","Inclusion Criteria:\n\n* Patients \\>18 years of age with breast cancer who are candidates for sentinel lymph node detection will be included.\n* N0 patients or patients who have undergone target axillary detection with good response\n\nExclusion Criteria:\n\n* Lymphadenectomy","ALL","18 Years","120 Years",{"count":21,"type":22},15000,"ESTIMATED","2 Years","OBSERVATIONAL","The current observational study aims to perform the sentinel lymph node in breast cancer in the usual way with technetium 99 and add a second tracer, indocyanine green. The objective is to evaluate the detection rate of the lymph node with indocyanine green compared to the usual technique.",[27],"Breast Cancer",[29,30,31],"lymph node detection","indocyanine green","breast cancer","RECRUITING","2024-09-08",{"date":35,"type":36},"2024-09-19","ACTUAL",{"date":38,"type":36},"2024-01-01",{"date":40,"type":22},"2029-01-01",{"name":42,"class":43},"Omphis Foundation","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100460801","use-of-glubran-2--in-axillary-lymphadenectomy-without-drain-100460801","NCT05280353","Use of Glubran 2 ® in Axillary Lymphadenectomy Without Drain","Seroma Control in Axillary Lymphadenectomy With Glubran 2® Without Drain. Multicenter, Prospective, Randomized Clinical Trial. GALA-ND Study (Glu Axillary Lymphadenectomy Ambulatory- no Drain)","GALA","Inclusion Criteria:\n\n* Over 18 years old\n* Conservative surgery for breast cancer with associated axillary lymphadenectomy\n\nExclusion Criteria:\n\n* Mastectomy\n* History of axillary surgery or ipsilateral axillary radiotherapy\n* ASA 4 patients. (ASA 3 patients selected)\n* Lack of adequate cognitive capacity and\u002For signed informed consent\n* Pregnancy","FEMALE",{"count":55,"type":22},134,"INTERVENTIONAL",[58],"NA","Axillary lymphadenectomy in breast cancer continues to be a common practice in certain patients. The use of sealants and drains continues to be a source of disagreement among the scientific community. That is why the study was designed to show whether the sealant reduces seroma after axillary lymphadenectomy without drainage.",[61],"Seroma Following Procedure","2024-09-02",{"date":64,"type":36},"2024-09-04",{"date":66,"type":36},"2022-04-01",{"date":68,"type":22},"2026-06-01",{"name":42,"class":43},""]